Alle Studien
RekrutierungPHASE3INTERVENTIONELL

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

Sjögren's disease is a long-term condition where the body's immune system attacks its own moisture-producing glands, leading to severe dry eyes, dry mouth, tiredness, and joint pain. Currently, there are limited treatments that tackle the root cause of the illness. This study is testing an investigational medicine called ianalumab (VAY736). It aims to calm the overactive parts of the immune system involved in Sjögren's. Around half the participants will receive monthly ianalumab injections under the skin for one year, while the other half will receive a dummy treatment (placebo) with no active medicine. Neither you nor your doctors will know which treatment you are receiving during the study. Researchers will closely track your symptoms, saliva production, and general health to see if ianalumab improves daily life and is safe to use.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Novartis Pharma
Einschreibeziel
570
Starten
16 Jul 2026
Geschätzte Fertigstellung
14 Aug 2033

Worum geht es in dieser Studie?

Sjögren's disease is an autoimmune condition. Normally, your immune system defends your body against germs. In Sjögren's, it mistakenly attacks healthy glands that make saliva and tears. This often causes severe dryness in the mouth and eyes, deep exhaustion, and joint aches. For many people, managing these symptoms day to day can be challenging, and existing medicines often only soothe the dryness rather than treating the underlying immune problem.

Ianalumab is an experimental medicine designed to target specific immune cells, known as B cells, which play a key role in causing the inflammation seen in Sjögren's. By reducing the activity of these cells, scientists hope ianalumab can protect the glands, help reduce dryness, and ease fatigue.

This trial is in 'Phase 3', which is the final stage of testing before a medicine can be approved for general use. To find out if the drug truly works, the trial compares ianalumab directly against a placebo (an identical-looking dummy injection). Comparing the two helps doctors be certain whether any improvements or side effects are genuinely caused by the medicine.

Wichtige Erkenntnisse

  • Testing a new monthly injection called ianalumab for adults with Sjögren's disease.
  • Aims to reduce immune inflammation, mouth dryness, and other daily symptoms.
  • Compares the active medicine against a dummy injection (placebo) over 52 weeks.
  • Requires regular clinic visits for blood tests, saliva checks, and health monitoring.
  • Participation is entirely voluntary, and you can withdraw at any time.

Wer könnte berechtigt sein?

This trial is open to adults aged 18 and over who have a confirmed diagnosis of Sjögren's disease and continue to experience high symptom levels, particularly severe dry mouth. To take part, your blood must show specific immune markers linked to the condition (called anti-Ro or SSA antibodies), and your mouth must still be able to produce a small amount of saliva.

People taking certain regular medicines, such as a stable dose of hydroxychloroquine or low-dose steroids, may still be able to take part.

You will not be eligible if you have other major, active autoimmune diseases, such as systemic sclerosis, active lupus, or severe blood vessel inflammation. You also cannot take part if you have fibromyalgia or have recently received certain immune-targeting treatments (such as rituximab) in the past nine months.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Do you have a confirmed medical diagnosis of Sjögren's disease?
  3. Do you suffer from significant, ongoing dry mouth symptoms?
  4. Have you tested positive for anti-Ro (SSA) antibodies in your blood?
  5. Are you free from other active autoimmune conditions, such as lupus or scleroderma?
  6. Have you avoided B-cell therapies (like rituximab) for at least the past 9 months?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join, your participation will last for at least 52 weeks (one year) of treatment. You will receive an injection just under the skin once every month. A computer will randomly decide whether you receive ianalumab or the placebo, and neither you nor your study doctor will choose or know which one you are getting.

You will visit the clinic regularly for health check-ups. At these visits, the research team will take blood samples, measure how much saliva you produce, test your tear production, and ask you to complete questionnaires about your symptoms and quality of life. You will also have follow-up visits after the treatment period ends so doctors can keep checking on your safety.

Potenzielle Risiken und Vorteile

You may experience an improvement in your Sjögren's symptoms, but this cannot be guaranteed, especially as you might receive the placebo. You will also receive careful, regular health monitoring from specialists throughout the trial. As with any new medicine, there is a risk of side effects. Common risks with injections can include redness or pain at the injection site, and medicines that calm the immune system can sometimes increase the risk of infections. Taking part is completely voluntary, and you can change your mind and leave the study at any time without affecting your normal NHS care.

Locations (72)

  • Sun Valley Arthritis Center Ltd
    Verifizierte Postleitzahl
    Peoria, United States· Rekrutierung
  • Unity Health Rheumatology
    Verifizierte Postleitzahl
    Searcy, United States· Rekrutierung
  • Medvin Clinical Research
    Verifizierte Postleitzahl
    Van Nuys, United States· Rekrutierung
  • Clinical Res Of W Florida
    Verifizierte Postleitzahl
    Clearwater, United States· Rekrutierung
  • GNP Research
    Verifizierte Postleitzahl
    Cooper City, United States· Rekrutierung
  • Clinical Research of West Florida Inc
    Verifizierte Postleitzahl
    Tampa, Vereinigte Staaten· Rekrutierung
  • Willow Rheumatology Wellness
    Verifizierte Postleitzahl
    Willowbrook, United States· Rekrutierung
  • Tufts Medizinisches Zentrum
    Verifizierte Postleitzahl
    Boston, Vereinigte Staaten· Rekrutierung
  • Clinical Research Inst of MI
    Verifizierte Postleitzahl
    Saint Clair Shores, United States· Rekrutierung
  • Arthritis Rheumatology and Bone Disease Associates PA
    Verifizierte Postleitzahl
    Voorhees Township, United States· Rekrutierung
  • St Lawrence Health System
    Verifizierte Postleitzahl
    Potsdam, United States· Rekrutierung
  • On Site Clinical Solutions Llc
    Verifizierte Postleitzahl
    Charlotte, Vereinigte Staaten· Rekrutierung

Häufige Fragen

What is a placebo and why is it used?

A placebo is a dummy treatment designed to look identical to the study medicine, but it contains no active ingredients. It is used so researchers can see if health changes are truly due to the medicine being tested.

Will I know if I am getting the real drug or the placebo?

No. This is a 'double-blind' trial, which means neither you nor your study doctor will know which injection you receive until the study is complete.

How is the study medicine given?

It is given as an injection under the skin (subcutaneous injection), usually in the tummy or thigh, once every month at the study clinic.

Can I continue taking my current Sjögren's medicines?

Certain medications, such as hydroxychloroquine or low-dose steroids, are often allowed if you have been on a stable dose, but the study team will review all your prescriptions first.

Does taking part cost anything?

No, the study medicine and all trial-related tests are provided free of charge. Most clinical trials also help cover reasonable travel expenses to and from hospital appointments.

Wie Sie mehr erfahren können

Novartis Pharma

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Two Arm, Double-blind, Phase III Study Assessing Efficacy an… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.